Gonadorelin: Six Men Had the Hypothalamic Signal Replaced by a Pump, and Testosterone Suppressed Them Anyway
Sheckter and colleagues published that in 1989, and it goes at the exact reasoning the compounded product is sold on. The dose and the route on the sales pages do match the labels, which is unusual here. The schedule does not: every therapeutic human use I found is a pump firing every 90 minutes.
What it is
Gonadorelin is a decapeptide, ten amino acids, and not an analogue of anything. The Canadian monograph says it has the same amino acid sequence as the gonadotropin releasing hormone the human hypothalamus makes.
The hypothalamus, the hormone control centre under the brain, sends GnRH down a short private blood supply to the anterior pituitary, a gland the size of a pea. The pituitary answers with luteinising hormone, LH, which tells the testicle to make testosterone, and follicle stimulating hormone, FSH, which supports sperm production. Those two are the gonadotropins.
The signal is a rhythm rather than a level. Belchetz, Plant, Nakai, Keogh and Knobil showed that in Science in 1978, in rhesus monkeys whose own GnRH supply had been destroyed by a lesion. Constant infusion failed to restore gonadotropin secretion. Once an hour restored it. Putting a restored animal back on continuous delivery produced a desensitization "of the processes responsible for gonadotropin release". It works like a doorbell, which brings someone when pressed at intervals and gets the wire pulled out of the wall when held down.
What is approved, and what for
Britain has a live human licence, PL 17509/0005, revised 30 August 2022, and everything it authorises is diagnostic. Section 4.1 covers two things: a single injection to evaluate the response of the gonadotropes, the pituitary cells that make LH and FSH, and evaluating what gonadotropic function is left after a pituitary tumour is removed or after surgery or irradiation. The dose is "100 micrograms, subcutaneously or intravenously", subcutaneous meaning into the fat just under the skin, given once.
Canada licensed something else. LUTREPULSE, from Ferring, induces ovulation in women with primary hypothalamic amenorrhea, meaning periods that never started because the hypothalamus is not signalling, and it is worn as a pod delivering 5 to 20 micrograms per pulse every 90 minutes. Behind it sit "four open, non-randomized, clinical studies" enrolling 268 women, of whom 48 had the licensed condition and 45 of those 48 ovulated, with no comparator arm reported anywhere in that section.
The United States approved two human products, Factrel in 1982 and the Lutrepulse Kit in 1989, and lists every strength of both as discontinued. The only currently marketed FDA approved Factrel I could find is a Zoetis cattle drug, "For use in animals only. Not for human use." Its two indications are ovarian cysts in cows, a single 2 mL injection into muscle, which is 100 micrograms, and heat synchronisation for insemination, at 2 to 4 mL, which that label glosses as 100 to 200 micrograms, given twice about nine days apart.
What the human record shows
On PubMed, gonadorelin and testosterone together in title or abstract returned 24 records. I read all 24 titles. Most are veterinary or otherwise unrelated, and none is a trial in men on testosterone. On ClinicalTrials.gov I found no registered study of gonadorelin in men taking testosterone either.
Three published studies I found gave it to men or boys for fertility, all by pump, and the 1989 experiment below is a fourth pump study in men. Zhang and colleagues, American Journal of Men's Health 2019: 28 men with congenital hypogonadotropic hypogonadism, meaning the hypothalamus never made GnRH from birth. Open label and not randomised, since "the participants were allowed to choose". Ten chose a pump at 10 micrograms every 90 minutes, 18 chose cyclical injections of hCG and hMG. The primary outcome was time to sperm density reaching 0.1 million per mL, a low bar the authors set deliberately, and on it the pump won, a median of 6 months against 14. On the proportion clearing that bar at all, 9 of 10 against 15 of 18, the difference was not significant. The same group followed 73 such men for three years in 2021, who chose between four treatments. The 70.2 percent reaching sperm production in that paper is a pooled figure for the pump and the cyclical injections together, and its denominator is that pooled subset rather than the 73, so it is not a gonadorelin figure. The third study used a pump in seven male infants.
The randomised placebo controlled trial is in women: NCT01976728, sponsored by Ferring, 39 randomised, 29 to gonadorelin across three pump doses and 10 to placebo pods. The primary efficacy analysis pooled the two higher doses, 9 of 18 ovulating against 0 of 10, at a one sided p of 0.0120, half the two sided figure a reader would compare against anything else. Note the lowest dose, 10 micrograms per pulse: a pump, in exactly the population the drug is licensed for, and one woman in nine ovulated.
Whose evidence this is
It belongs to a pump running day and night, every 90 minutes in the fertility studies and every two hours in the 1989 experiment, and to men who make no GnRH at all, whose pituitary has never been asked to do anything and who have no androgen feedback holding it down, their own testosterone being close to zero. That is the reverse of the man being sold the product, and I found no published human study in which gonadorelin was given as an isolated injection a couple of times a week and anything downstream was measured.
The evidence for the job itself belongs to a different drug, human chorionic gonadotropin, which acts on the LH receptor in the testicle directly, and even that is thin: Hsieh and colleagues, Journal of Urology 2013, is a chart review of 26 hypogonadal men on testosterone plus hCG into muscle every other day, with no comparison group.
The transfer can be shown rather than asserted. Empower Pharmacy's page "Compounded Gonadorelin in Men's Health" has three references: a Mayo Clinic drug page, a DrugBank entry, and Zhang 2019.
Where the 100 micrograms came from
What circulates is 100 micrograms under the skin, two or three times a week, reported here as convention rather than as advice. The 100 is not invented. It is the licensed British diagnostic dose, and it was the strength of the smallest discontinued American vial. The cattle label uses it too, for one of its two indications, while the other runs 100 to 200 micrograms twice. The route matches as well: subcutaneous is on the British label in black and white, and it is what people are using.
What drifts is the schedule, and the arithmetic below is mine while the numbers come from the documents named. A pulse every 90 minutes is 16 a day and 112 a week, which is the Canadian licence, the Ferring trial and the male fertility pump studies. Two injections a week is 2 of those 112. On quantity, 5 to 20 micrograms across 112 pulses is 560 to 2,240 micrograms a week against 200 to 300 on the circulating schedule, so bottom to bottom and top to top it is about a third down to about an eighth of it. The drug also clears fast, at a half life of about 4 minutes on the British label, so Monday's injection is long gone before Thursday's.
The vendor pages answer that directly. FormBlends says the goal is not to replicate physiologic pulsatility but to provide periodic stimulation, which may be right, and I found no study testing it. Its own pump block runs 75 to 100 micrograms per pulse, four to twenty times the Canadian licensed range, and it does attribute that figure, to a 2020 Jayasena paper in Human Reproduction. That is one of four papers the page cites that my searches could not locate. Searching gonadorelin in title or abstract across the Journal of Clinical Endocrinology and Metabolism, Human Reproduction, Fertility and Sterility and Andrology for 2019 to 2023 returned exactly one record, and it is none of the four. A separate author search and a journal search, both aimed at a different one of the four, returned nothing. I did not check every citation on that page and I am not claiming those papers exist nowhere.
The experiment that tested the premise
Sheckter, Matsumoto and Bremner published it in the Journal of Clinical Endocrinology and Metabolism in February 1989, under a title that gives the answer away: testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary.
Six men with hypogonadotropic hypogonadism were put on "physiological doses of GnRH (5 micrograms every 2 h, sc by automatic infusion pump) for 6 weeks". Once their LH and FSH were normal they were given testosterone enanthate, 200 mg into muscle weekly for 8 weeks, on top of the pump, then the pump alone again for 8 weeks. All six went through all three periods, so there are no arms to confuse.
With the pump running unchanged, mean LH fell to about half, 18 against 37 micrograms per litre, and FSH to about 30 percent, 39 against 128. The rise the pituitary produced in answer to each pulse shrank too, from 31 to 17. Everything came back 8 weeks after the testosterone stopped. Their conclusion: testosterone and its metabolites "inhibit LH and FSH secretion by a GnRH-independent mechanism, probably directly on the pituitary gland, in man".
Read that against the pitch. The premise of the substitution is that testosterone silences the hypothalamus, so you replace the hypothalamic signal and the chain runs again. These six men had it replaced, mechanically, at a physiological interval, and were suppressed anyway. The limits are real: six men, in 1989, with a hypothalamic and pituitary disorder, on a testosterone dose above the therapeutic range, and I found no modern replication.
The British licence says the same thing in regulatory language. Section 4.5 tells prescribers the test "should be conducted in the absence of other drugs which directly affect the pituitary secretion of gonadotropins", giving preparations that contain androgens among the examples of that class. It is also why swapping gonadorelin in for hCG is not like for like: hCG acts past the pituitary, while gonadorelin acts on the pituitary, the organ the testosterone is suppressing.
What the regulators have on file
No safety withdrawal sits on the American record. I read 21 CFR 216.24, which lists products withdrawn or removed from the market because they "have been found to be unsafe or not effective", current as of 6 August 2026, and gonadorelin appears nowhere in it. That is not a document giving a reason, and I looked for one: in the Federal Register on 10 August 2026, Lutrepulse returned zero documents, Factrel four that were all veterinary or anti-doping, gonadorelin 55 of which 34 are Medicare or Medicaid payment rules, and both application numbers nothing at all. No determination in either direction, and no reason should be read into that silence.
FDA's page on bulk drug substances under section 503A gives three routes a substance can qualify by. I downloaded FDA's nominated bulk substances document dated 14 May 2026 and searched the extracted text: gonadorelin appears in none of the three categories, and neither does the abbreviation GnRH. Which route compounders rely on is not something I found stated in an FDA document, and I will not characterise it from my own knowledge.
The rule change that opened this market is about hCG rather than gonadorelin. FDA's notice to compounders, current as of 5 March 2020, says transitioning biological products "will not be eligible for the exemptions for compounded drugs" from 23 March 2020, and human chorionic gonadotropin is the first of the four substances it names as affected.
What could go wrong
The label record is unremarkable and should be reported that way. The British adverse reaction table lists nothing at common or very common frequency. Pain, swelling and itching are uncommon, and a longer list sits in the rare column, between 1 in 10,000 and 1 in 1,000, including hypersensitivity reactions, a fast heartbeat, hives, redness of the skin and of the eyelid, and antibodies against the peptide.
Section 4.4 puts its reassurance and its caveat in consecutive sentences. No hypersensitivity reactions have been encountered "following the administration of a single 100 micrograms dose of gonadorelin used for diagnostic purposes", and "patients in whom re-administration is considered, particularly by the intravenous route, should be carefully observed". Read that against roughly a hundred to a hundred and fifty injections a year. The same section rules the drug out in pregnancy and says it is not recommended in patients with a pituitary adenoma, a benign pituitary tumour common enough to be found by accident, because a sudden bleed into it may occur.
The only real world adverse event figures in men I found are Zhang's, and they describe a continuously worn pump rather than an injection: of the 10 on the pump, 9 had red hardened skin at the needle site and one a small abscess there, against none of the 18 on injections.
The structural risk is the one this compound turns on. Continuous, unpulsed exposure quietens the pituitary down: the Canadian overdose section says continuous, non-pulsatile exposure could temporarily reduce pituitary responsiveness, the 1978 monkey work showed a restored animal losing gonadotropin release again when put back on continuous delivery, and Zhang reports "a reduced sensitivity to the pulsatile GnRH was noticed after a period of administration". The next sentence in the paper qualifies it, citing a 2004 report that secretion can be restored after a brief withdrawal or a dose increase, and in the study itself the dose was raised in three men and lowered in one to hold testosterone normal. So the failure mode is the axis quietening down, and there it was managed rather than permanent.
What I could not find an answer to
Whether a twice weekly injection under the skin changes LH, FSH, testosterone inside the testicle, testicular volume or sperm count in a man taking testosterone. I found no published study measuring it, in either direction.
Whether the 1989 result generalises. Six men, a pituitary disorder, a testosterone dose above the therapeutic range, and no modern replication I could locate.
Why the two American products went away. And whether the figure the vendor pages lead with, 71 percent of men on testosterone keeping their sperm count up on twice weekly gonadorelin, has a paper behind it. My searches found neither.
What the selling rests on
Most entries here end with a dose that has no derivation behind it. This one ends somewhere stranger. The amount is a real label number, the route is on the label too, and the compound is the human hormone itself. What is missing is the rhythm, and the rhythm is the whole pharmacology: a hundred and twelve doses a week at the licensed 90 minute interval is what the Canadian licence, the randomised trial and the male pump studies deliver, against the two or three that people inject.
Underneath sits the 1989 experiment, which went at something more basic and came back the wrong way. If testosterone suppresses the pituitary directly, then restoring the hypothalamic signal, on any schedule, is fixing a step that was not the one blocked. Six men is six men, and that is a hypothesis rather than a verdict. It is also the closest published human test of the proposition that I could find, and it appears on no sales page I read.
Go to PubMed and open PMID 2493030. The abstract is free and a few hundred words long, and it tells you what happened to those six men without anyone needing to interpret it for you.
Frequently asked
Is gonadorelin approved?
In Britain, yes, and only as a diagnostic. Its licence covers a single injection to test how the pituitary's gonadotrope cells respond, and evaluating what gonadotropic function is left after a pituitary tumour is removed or after surgery or irradiation. In Canada it is licensed for inducing ovulation in women with primary hypothalamic amenorrhoea, delivered by a wearable pump, subcutaneous use only. In the United States, two human applications were approved, Factrel in 1982 and the Lutrepulse Kit in 1989, and openFDA lists every strength of both as discontinued. The only currently marketed FDA approved product carrying the Factrel name that I could find is a cattle drug whose label says it is not for human use.
Does gonadorelin keep the testicles working during testosterone therapy?
I could not find a published trial or a registered trial that measures it. Every human study of gonadorelin in males that I located delivered it by an infusion pump running around the clock, every 90 minutes in the fertility studies, in men whose brains make no gonadotropin releasing hormone at all, which is close to the opposite of a man whose pituitary is being suppressed by weekly testosterone. The closest published human test of the mechanism is from 1989: six men with hypogonadotropic hypogonadism were kept on a GnRH pump, and when testosterone was added on top with the pump still running, LH fell to about half and FSH to about 30 percent. The authors concluded that testosterone suppresses those hormones by a route that does not run through GnRH, acting directly on the pituitary.
Where does the 100 microgram figure come from?
From product labels, reported here as label arithmetic rather than as a recommendation. 100 micrograms under the skin or into a vein is the licensed British diagnostic dose for a single test injection, and 0.1 mg base was the smallest of the three discontinued American Factrel vials. The Zoetis cattle label reaches the same figure for one of its two indications, a single 2 mL injection into muscle of a 50 microgram per mL solution, while its heat synchronisation protocol runs 100 to 200 micrograms given twice. What none of those labels covers is a fixed twice or three times weekly schedule in a man, which is convention and not a licensed use.
Is gonadorelin safe?
The label record is unremarkable and should be read that way rather than as a clearance. The British label's adverse reaction table lists nothing at common or very common frequency; pain, swelling and itching are uncommon, and hypersensitivity reactions, a fast heartbeat, hives, redness of the skin and of the eyelid and antibodies against the peptide sit in the rare column, meaning between 1 in 10,000 and 1 in 1,000. Two limits matter. The label's reassurance about hypersensitivity is explicitly about a single diagnostic dose, and it tells prescribers to observe patients carefully if the injection is repeated. And it says gonadorelin and its analogues are not recommended in patients with a pituitary adenoma, because a sudden bleed into that tumour may occur. The one set of real world adverse event figures in men I found describes a continuously worn pump, not injections: 9 of 10 men on the pump had red hardened skin at the needle site and one developed a small abscess there.
Why were the American gonadorelin products discontinued?
I could not find a document giving a reason, and the absence of one should not be read either way. Gonadorelin appears nowhere in 21 CFR 216.24, the regulation listing products withdrawn or removed from the market for reasons of safety or effectiveness, in the version current as of 6 August 2026, so no safety withdrawal is on that record. Searching the Federal Register on 10 August 2026, Lutrepulse returned zero documents, Factrel returned four that were all veterinary or anti-doping, and each of the two application numbers returned nothing. I have seen it asserted on vendor pages that the discontinuation was commercial. I found no FDA document saying so.
This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.
Get the next one in your inbox
Free. One email a week at most. Unsubscribe in one click.
Double opt-in · No spam · Unsubscribe anytime
More in Melanocortin and hormonal
- Kisspeptin-10: FDA Counted 24 Human Studies, and Found One That Went Under the SkinThe product put to the compounding committee was for injection under the skin and into a muscle. FDA found no human study by the muscle route at all, and the whole under the skin record it identified is one arm of one 2011 study in healthy women in which no reproductive hormone moved. The committee voted 0 to 11 against.
- Melanotan I Really Is the Approved Drug. What Circulates Is Not the Approved Product.One chemical database record carries both names and the formula matches the label. What is approved is a 16 mg rod a trained physician pushes under the skin every two months for a rare light sensitivity disease, and the headline effect from its pivotal trial is filed by the European assessors under post hoc analyses.
- Oxytocin Is Approved as an Injection for the Uterus and Sold as a Spray for the MindThe gap here is route, not indication. There was once an approved American nasal oxytocin and FDA's database still lists it, marked discontinued. Both of the largest autism trials I found missed their primary endpoint, and whether sniffing it reaches the brain is still argued inside the papers that measured it.